目的 探讨重组人血管内皮抑制素联合托泊替康治疗复发性卵巢癌的临床疗效。方法 选取2014年3月-2016年1月中国人民解放军第273医院收治的复发性卵巢癌患者72例，随机分为对照组和治疗组，每组各36例。对照组患者静脉滴注注射用盐酸托泊替康，1.2 mg/m²加入生理盐水100 mL中，滴注30 min，连续用药5 d。治疗组在对照组治疗基础上静脉滴注重组人血管内皮抑素注射液，15 mg加入生理盐水500 mL，静脉滴注5 h，连续给药14 d。每21天为1个疗程，所有患者治疗2个疗程。观察两组的临床疗效，同时比较两组患者生活质量和毒副反应发生情况。结果 治疗后，对照组总有效率30.56%，临床受益率为58.34%，治疗组总有效率为47.22%，临床受益率为77.78%，两组总有效率和临床收益率比较差异均具有统计学意义（P<0.05）。对照组和治疗组的生活质量改善率分别为36.11%、52.78%，两组比较差异有统计学意义（P<0.05）。与对照组比较，治疗组患者白细胞减少、贫血、血小板减少、恶心呕吐的发生率显著降低，两组比较差异有统计学意义（P<0.05），两组肝功能异常发生率比较差异无统计学意义。结论 重组人血管内皮抑素联合托泊替康治疗复发性卵巢癌具有较好的临床疗效，可以改善患者的生活质量，具有一定的临床推广应用价值。

Objective To investigate the clinical effect of recombinant human endostatin combined with topotecan in treatment of recurrent ovarian cancer. Methods Patients (72 cases) with recurrent ovarian cancer in 273th Hospital of the Chinese People's Liberation Army from March 2014 to January 2016 were randomly divided into control and treatment groups, and each group had 36 cases. The patients in the control group were iv administered with Topotecan Hydrochloride for injection, 1.2 mg/m² added into normal saline 100 mL, and dripped in 30 min for 5 d. The patients in the treatment group were iv administered with Recombinant Human Endostatin Injection on the basis of the control group, 15 mg added into normal saline 500 mL, and dripped in 5 h for 14 d. Every 21 d was as a course of treatment, and the patients in two groups were treated for two courses. After treatment, the clinical efficacies were evaluated, and the life quality and adverse reaction in two groups were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 30.56% and 47.22%, and the clinical benefit rates in two groups were 58.34% and 77.78%, respectively, and there were differences between two groups (P<0.05). The life quality improvement rates in the control and treatment groups were 36.11% and 52.78%, and there were differences between two groups (P<0.05). Compared with the control group, the incidences of leukopenia, nausea and vomiting, anemia, and thrombocytopenia in the treatment group were significantly reduced, and there were differences between two groups (P<0.05). The incidence of abnormal liver function was similar between two groups, and there were no statistical significance. Conclusion Recombinant human endostatin combined with topotecan has clinical curative effect in treatment of recurrent ovarian cancer, and can improve the life quality, which has a certain clinical application value.